Global Buccal Drug Delivery Market, By Indication (Pain Management, Smoking Cessation, Angina Pectoris, Cough and Others), Type (Non-Attached Drug Delivery Systems and Bio-Adhesive Drug Delivery Systems), Design (Matrix Type and Reserviour Type), Dosage Forms (Solid Buccal Adhesive Dosage Forms, Semi-Solid Buccal Adhesive Dosage Forms, Liquid Buccal Adhesive Dosage Forms), Drugs (Oral Bioadhesive Formulation, Sublingual Formulation and Others), End Users (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2030.
Buccal Drug Delivery Market Analysis and Size
Buccal drug delivery systems have gained huge growth because of the constant research and development in this field. Buccal delivery is considered the most feasible and preferred choice compared to oral dosage form, particularly among elderly patients. The sublingual films segment is projected to grow at the highest rate during the forecast period 2023-2030. The market is still developing in terms of new product launches because of the limited identification of suitable drug candidates.
Data Bridge Market Research analyses a growth rate in the buccal drug delivery market in the forecast period 2023-2030. The expected CAGR of buccal drug delivery market is tend to be around 9.8% in the mentioned forecast period. The market value is USD 3.38 billion in 2022, and it would grow upto USD 7.13 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Buccal Drug Delivery Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Pain Management, Smoking Cessation, Angina Pectoris, Cough and Others), Type (Non-Attached Drug Delivery Systems and Bio-Adhesive Drug Delivery Systems), Design (Matrix Type and Reserviour Type), Dosage Forms (Solid Buccal Adhesive Dosage Forms, Semi-Solid Buccal Adhesive Dosage Forms, Liquid Buccal Adhesive Dosage Forms), Drugs (Oral Bioadhesive Formulation, Sublingual Formulation and Others), End Users (Hospitals, Homecare, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Lupin (India), Teva Pharmaceuticals Industries Ltd. (Israel), Zydus Group (India), Bausch Health Companies Inc (Canada), Collegium Pharmaceutical, Inc. (U.S.), GSK plc (U.K.), Abbvie, Inc (U.S.), AstraZeneca (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Sanofi (France), Bayer AG (Germany), Takeda Pharmaceutical Company Limited (Japan), Novartis AG (Switzerland), Indivior PLC (U.S.), Novo Nordisk A/S (Denmark), NAPP PHARMACEUTICALS LIMITED (U.S.), APR (Switzerland), ARKRAY, Inc (Japan)
|
|
Market Opportunities
|
|
Market Definition
Buccal drug delivery is a substitute technique for an oral drug delivered in which the drug is administrated through buccal mucosa of oral cavity. The drug is usually placed between the upper gums and cheeks for the treatment of numerous disease and condition. Buccal drug delivery is considered suitable for use among the hospital patients. The biofluid interaction of the buccal drug delivery is reduced by such delivery systems. These systems even help in providing high concentration particularly at target area.
Buccal Drug Delivery Market Dynamics
Drivers
- Increasing research by Different Community Hospitals
Rise in admission in hospitals, particularly of elderly patients, and product development and research by numerous community hospitals are increasing the segment growth. Studies conducted by several hospitals bring novelty and increase the commercialization of the formulation. For instance, three community hospitals in Japan in 2020 conducted in vitro and in vivo studies to develop mucoadhesive microparticle-laden gels for oral mucositis. The research confirmed that the drug's increased concentration at the target site and faster treatment than traditional dosage forms are most likely to improve the adoption. Furthermore, several hospitals in highly developed countries are much involved in the study and development of buccal mucoadhesive formulation which includes potent analgesics, insulin, and drugs to treat heart failure. Ambulatory centers are anticipated to witness the huge growth during the forecast period, followed by the other segment that includes home health, clinics, and OTC medications.
Opportunities
- Increasing Demand of Sublingual Films
The sublingual films are anticipated to grow at the highest rate during the forecast period 2023-2030. Multiple factors are responsible for the segment's growth, such as increased research to develop controlled release formulation and immediate availability of high drug concentration at a target site. These formulations are used widely being used in anti-addiction treatments and emergency care centers due to their faster onset of action.
- Increase in Smoking Addiction
Buccal drug delivery is often the most recommended and effective formulation for treating patients with smoking or nicotine addiction. Several studies have confirmed that nicotine lozenges are highly effective in delivering a greater concentration of the drug than gums or other dosage forms. It is also a good alternative for those hesitant to constantly chew on gums and a great choice to cease low and high-dependent smoking. Thus, this factor boost the market growth.
Restraints/Challenges
- High Cost of Buccal Drug Delivery System
The vast expenditure associated with the system are majorly affecting the market's growth. The high capital cost invested in the buccal drug delivery system manufacturing is a major restrain in the market. Several medium and small-scale manufacturers are not able to manage with the high capital cost. Thus, it impedes the market growth.
This buccal drug delivery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the buccal drug delivery market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Buccal Drug Delivery Market Scope
The buccal drug delivery market is segmented on the basis of indication, type, design, forms, drugs, end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Pain Management
- Smoking Cessation
- Angina Pectoris
- Cough
- Others
Type
- Non-Attached Drug Delivery Systems
- Bio-Adhesive Drug Delivery Systems
Design
- Matrix Type
- Reserviour Type
Forms
- Solid Buccal Adhesive Dosage Forms
- Buccal tablets
- Wafers
- Lozenges
- Semi-Solid Buccal Adhesive Dosage Forms
- Gels
- Buccal patches
- Buccal films
- Liquid Buccal Adhesive Dosage Forms
Drugs
- Oral Bioadhesive Formulation
- Hydrocartisone succinate
- Hypromellose
- Miconazole
- Chlorohexidine
- Sublingual Formulation
- Glycerin trinitrate
- Others
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Buccal Drug Delivery Market Regional Analysis/Insights
The buccal drug delivery market is analyzed and market size insights and trends are provided by indication, type, design, forms, drugs, end-users as referenced above.
The major countries covered in the buccal drug delivery market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the buccal drug delivery market because of the wide presence of a large number of major market players, improved research to identify suitable drug candidates, major investment by major market players to improve the development of innovative formulations, and improved diagnosis.
Asia-Pacific is considered to have the most lucrative growth because of increase in the elderly population, the huge development of pharmaceutical industry, and a massive increase in market players.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Buccal Drug Delivery Market Share Analysis
The buccal drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to buccal drug delivery market.
Key players operating in the buccal drug delivery market include:
- Pfizer Inc. (U.S.)
- Lupin (India)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- Zydus Group (India)
- Bausch Health Companies Inc (Canada)
- Collegium Pharmaceutical, Inc. (U.S.)
- GSK plc (U.K.)
- Abbvie, Inc (U.S.)
- AstraZeneca (U.K.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Sanofi (France)
- Bayer AG (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
- Novartis AG (Switzerland)
- Indivior PLC (U.S.)
- Novo Nordisk A/S (Denmark)
- NAPP PHARMACEUTICALS LIMITED (U.S.)
- APR (Switzerland)
- ARKRAY, Inc (Japan)
SKU-